Patent SG-11201408428P-A (SG)
Title: Dosage regime of fusion compounds
Inventor: SEKARAN SHAMALA DEVI K C
IPC: A61P31/00
Filed: 2013-06-25
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/003536 Al (51) International Patent Classification: C07K19/00 (2006.01) A61P 31/00 (2006.01) A61K38/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/MY2013/000114 (22) International Filing Date: 25 June 2013 (25.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PI 2012002923 26 June 2012 (26.06.2012) MY (71) Applicant: BIOVALENCE SDN. BHD. [MY/MY]; 21, Jalan SS25/34, Taman Mayang Industrial Park, Petaling Jaya 47301 (MY). (72) Inventors: SEKARAN, Shamala Devi K C; 17 Jin 10/10 F, Petaling Jaya 46000 (MY). ROTHAN, Hussin A.; 3-7- 7 OUG Condominium, Jin 3A/155, Kuala Lumpur 58000 (MY). UNG, Eng Huan; No. 2, Lorong Ujana Kingfisher 9, Kingfisher Ujana 88450, Kota Kinabalu, Sabah (MY). ABU BAKAR, Ag. Muhammad Sagaf; P.O. Box 81, Pos Mini, Central Plaza, 88300 Kota Kinabalu, Sabah (MY). (74) Agents: JEFFREY, Fiona Teresa et al.; Marks & Clerk (Malaysia) SDN BHD, PO Box 11182, 50738 Kuala Lum­ pur (MY). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: DOSAGE REGIME OF FUSION COMPOUNDS m m o o i i 61 ATGGCCATGGGGCGTATTTGCCGTTGCATTTGCGGCCGTGGCATTTGCCGCTGCATCTGT 21 121 41 181 61 241 81 301 101 361 121 421 141 481 TATACCGGCAACTATGAAAACCTGCAGACCGCGGCGCATAAAATTCGTGAAAACATCGAT 161 541 181 601 201 661 221 721 241 781 261 841 281 901 301 961 321 1021 341 1001 361 ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCG MKYLLPTAAAGLLLLAAQPA MAMGRICRCICGRGICRCIC GGCGTGCCGGGTGTTGGTGTTCCGGGTGTGGGTGGTGCGACCGGATCCGATGTGAACTTT V G V V V D N GATCTGAGCACCGCGACCGCGAAAACCTATACCAAATTCATCGAAGATTTTCGTGCGACC DLSTATAKTYTKFIEDFRAT CTGCCGTTTAGCCATAAAGTGTATGATATCCCGCTGCTGTATAGCACCATTAGCGATAGC LPFSHKVYDI PLLYSTISDS CGTCGTTTTATTCTGCTGGATCTGACCAGCTATGCGTATGAAACCATTAGCGTGGCGATT RRFILLD.LTSYAYETISVAI GATGTGACCAACGTGTATGTGGTGGCGTATCGTACCCGTGATGTGAGCTACTTTTTCAAA DVTNVYVVAYRTRDVSYFFK GAAAGCCCGCCGGAAGCGTACAACATTCTGTTTAAAGGCACCCGTAAAATTACCCTGCCG N K K YTGNYENLQTAAHKIRENID CTGGGCCTGCCGGCCCTGAGCAGCGCGATTACCACCCTGTTTTATTATAACGCGCAGAGC LGLPALSSAITTLFYYNAQS GCGCCGAGCGCGCTGCTGGTGCTGATTCAGACCACCGCGGAAGCGGCGCGTTTTAAATAT APSALLVLIQTTAEAARFKY ATTGAACGCCACGTGGCGAAATATGTGGCGACCAACTTTAAACCGAACCTGGCCATTATT H V A K V N K N AGCCTGGAAAACCAGTGGAGCGCCCTGAGCAAACAAATTTTTCTGGCCCAGAACCAGGGC SLENQWSALSKQIFLAQNQG GGCAAATTTCGTAATCCGGTGGATCTGATTAAACCGACCGGCGAACGTTTTCAGGTGACC GKFRN PVDL 1 KPTGERFQVT AATGTGGATAGCGATGTGGTGAAAGGCAACATTAAACTGCTGCTGAACAGCCGTGCGAGC N V N N ACCGCGGATGAAAACTTTATTACCACCATGACCCTGCTGGGCGAAAGCGTGGTGGAATTC TADENFITTMTLLGESVVEF CCGTGGGCGCTGTGGAAAACCATGCTGAAAGAACTGGGCACGATGGCGCTGCATGCGGGT W W M K M H AAAGCGGCGCTGGGTGCGGCAGCGGATACCATTAGCCAGGGCACCCAGGTTCCGGGCGTG KAALGAAADT I SQGTQVPGV GGCGTTCCGGGCGTTGGTAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA GVPGVGKLAAALEHHHHHH* (57) Abstract: Use of at least one fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, poly­ peptide B; and at least one polypeptide A which is antimi­ a crobial peptide and/or at least one Cationic AntiMicrobial Peptide, polypeptide C for the preparation of a medicament for treating a cancer and/or microbial infection wherein a the medicament is suitable for oral administration pre food in­ take. O CJ o & WO 2014/003536 Al III llll IIII III III Hill III III III Hill II llll llll 111 111 mill llll 111 llll Declarations under Rule 4.17: Published: — ofinventorship (Rule 4.17(iv)) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))